Whitepaper: SARS-CoV-2 Omicron spike protein and antibodies available
Posted: 21 December 2021 | Sino Biological Inc. | No comments yet
Sino Biological has developed recombinant Omicron Spike RBD protein and antibody reacting with Omicron to support the study of Omicron variant.
Sino Biological has developed recombinant Omicron Spike RBD protein and antibody reacting with Omicron to support the study of Omicron variant. More Omicron antigens, including B.1.1.529 S-ECD, S1, and Nucleocapsid, are coming soon.
Related content from this organisation
- Sino Biological announces construction of its new US-Based centre for bioprocessing
- Application note: Afucosylated mAb expression & antibody efficacy
- Whitepaper: Recombinant protein expression using a BEVS
- Sino Biological and Ainnocence partner to offer next-generation antibody development CRO services
- Sino Biological invests over 200M RMB to establish new subsidiaries in Taizhou and Suzhou, China
Related topics
Antibodies, Biomarkers, Biopharmaceuticals, Disease Research, Immunology
Related organisations
Sino Biological Inc.